← MADRIGAL PHARMACEUTICALS, INC.
| Annual Trend | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $48k |
$558k
+1055.21%
|
$7.7m
+1274.73%
|
$0
-100.00%
|
$0 | $0 | $0 | $0 | $180.1m |
$958.4m
+432.05%
|
$1.3b
+33.97%
|
|
| Cost of Revenue | $16.0m |
$24.9m
+56.10%
|
$33.1m
+32.52%
|
$72.3m
+118.77%
|
$184.8m
+155.53%
|
$205.2m
+11.01%
|
$0
-100.00%
|
$0 | $6.2m |
$444.7m
+7034.17%
|
$109.4m
-75.39%
|
|
| Gross Profit (Calculated) (derived) | ($15.9m) |
($24.4m)
-53.07%
|
($25.4m)
-4.10%
|
($72.3m)
-184.86%
|
($184.8m)
-155.53%
|
($205.2m)
-11.01%
|
$0
+100.00%
|
$0 | $173.9m |
$513.7m
+195.42%
|
— | |
| General and Administrative Expense | $9.3m | $7.7m | $15.3m | $22.6m | $21.9m | $37.3m | $48.1m | $108.1m | $435.1m | $813.8m | $340.4m | |
| Operating Costs and Expenses | — | — | — | — | — | — | — | — | — | $56.1m | — | |
| Operating Expenses | $25.2m | $32.1m | $40.7m | $95.0m | $206.7m | $242.5m | $293.6m | $380.5m | — | $1.3b | $1.5b | |
| Operating Income (Loss) | ($25.2m) |
($32.1m)
-27.11%
|
($40.7m)
-26.89%
|
($95.0m)
-133.45%
|
($206.7m)
-117.61%
|
($242.5m)
-17.33%
|
($293.6m)
-21.07%
|
($380.5m)
-29.61%
|
($497.9m)
-30.85%
|
($300.1m)
+39.72%
|
($322.6m)
-7.50%
|
|
| Interest Income, Other | $48k | $558k | $7.7m | $11.0m | $4.3m | $363k | $2.2m | — | — | — | $35.1m | |
| Other Nonoperating Income (Expense) | — | — | — | — | — | — | — | — | — | ($463k) | — | |
| Interest Expense (non-operating) | $1.2m | — | — | — | $0 | $0 | $4.0m | $12.7m | $14.7m | $22.3m | $31.5m | |
| Other Income | — | $350k | $200k | — | $100k | $273k | $0 | — | — | — | — | |
| Interest Income (Expense), Nonoperating, Net | — | — | — | — | — | — | — | — | $32.0m | — | $35.1m | |
| Income (Loss) from Continuing Operations before Income Taxes, Domestic | — | — | — | — | — | — | — | — | — | ($158.5m) | ($325.1m) | |
| Income Tax Expense (Benefit) | — | — | — | — | — | — | $0 | $0 | $0 | $0 | — | |
| Net Income (Loss) Attributable to Parent | ($26.4m) |
($31.2m)
-18.06%
|
($32.8m)
-5.32%
|
($83.9m)
-155.85%
|
($202.2m)
-140.92%
|
($241.8m)
-19.58%
|
($295.4m)
-22.12%
|
($373.6m)
-26.50%
|
($465.9m)
-24.69%
|
($288.3m)
+38.12%
|
($325.1m)
-12.77%
|
|
| Net Income (Loss) Available to Common Stockholders, Basic | ($26.4m) | ($31.2m) | — | — | ($13) |
($15)
-11.76%
|
($17)
-17.77%
|
($20)
-16.02%
|
($22)
-9.55%
|
($13)
+41.32%
|
($325.1m)
-2529922078.99%
|
|
| Earnings Per Share, Basic | ($26.4m) | ($31.2m) | — | — | ($13.09) | ($14.63) | ($17.23) | ($19.99) | ($21.90) | ($12.85) | ($13.99) | |
| Earnings Per Share, Diluted | ($5.07) | ($2.54) | ($2.22) | ($5.45) | ($13.09) | ($14.63) | ($17.23) | ($19.99) | ($21.90) | ($12.85) | ($13.99) | |
| Weighted Average Number of Shares Outstanding, Basic | — | — | — | — | 15.4m | 16.5m | 17.1m | 18.7m | 21.3m | 22.4m | 22.9m | |
| Weighted Average Number of Shares Outstanding, Diluted | — | — | — | — | 15.4m | 16.5m | 17.1m | 18.7m | 21.3m | 22.4m | 22.9m | |
| Additional Financial Items | ||||||||||||
| Costs and Expenses | — | — | — | — | — | — | — | — | $678.0m | — | — |
Values abbreviated: b = billions, m = millions, k = thousands. Per share data in USD.